| Intestinal immune network for IgA production |
1.60 |
3.77e-1 |
38/48 (79.17%) |
HLA-DQA1;HLA-DPB1;CXCL12;...
|
| Cell adhesion molecules |
1.58 |
3.45e-1 |
118/148 (79.73%) |
HLA-DQA1;SDC1;VCAM1;...
|
| Various types of N-glycan biosynthesis |
1.55 |
3.59e-1 |
26/39 (66.67%) |
MAN1C1;B4GALT3;DDOST;...
|
| Thyroid hormone synthesis |
1.51 |
4.01e-1 |
66/75 (88%) |
GNAS;CREB1;FXYD2;...
|
| Allograft rejection |
1.51 |
3.45e-1 |
32/38 (84.21%) |
HLA-DQA1;HLA-DPB1;HLA-DOB;...
|
| Vibrio cholerae infection |
1.50 |
3.17e-1 |
44/50 (88%) |
ATP6V1D;GNAS;PLCG2;...
|
| Porphyrin and chlorophyll metabolism |
1.48 |
3.49e-1 |
23/43 (53.49%) |
CP;PPOX;FECH;...
|
| Riboflavin metabolism |
1.48 |
3.18e-1 |
7/8 (87.5%) |
ENPP1;BLVRB;ACP1;...
|
| Complement and coagulation cascades |
1.45 |
3.63e-1 |
76/85 (89.41%) |
A2M;C1QA;C1QB;...
|
| Graft-versus-host disease |
1.44 |
3.52e-1 |
32/42 (76.19%) |
HLA-DQA1;HLA-DPB1;HLA-DOB;...
|
| Autoimmune thyroid disease |
1.41 |
4.16e-1 |
46/53 (86.79%) |
HLA-DQA1;HLA-DPB1;HLA-DOB;...
|
| Inflammatory bowel disease |
1.40 |
4.01e-1 |
58/65 (89.23%) |
HLA-DQA1;SMAD3;HLA-DPB1;...
|
| Notch signaling pathway |
1.38 |
4.56e-1 |
49/59 (83.05%) |
HEY1;RBPJ;NOTCH1;...
|
| Collecting duct acid secretion |
1.38 |
4.41e-1 |
22/27 (81.48%) |
ATP6V1D;ATP6V0A4;ATP6V1A;...
|
| Toxoplasmosis |
1.37 |
4.47e-1 |
103/112 (91.96%) |
HLA-DQA1;HLA-DPB1;LAMA2;...
|
| Systemic lupus erythematosus |
1.35 |
4.68e-1 |
45/135 (33.33%) |
HLA-DQA1;C1QA;C1QB;...
|
| Glycerolipid metabolism |
1.35 |
4.54e-1 |
44/61 (72.13%) |
MBOAT2;AKR1B10;ALDH2;...
|
| Rheumatoid arthritis |
1.33 |
4.67e-1 |
78/93 (83.87%) |
ATP6V1D;HLA-DQA1;VEGFA;...
|
| Amino sugar and nucleotide sugar metabolism |
1.32 |
4.81e-1 |
38/48 (79.17%) |
UGP2;NAGK;PMM2;...
|
| Inositol phosphate metabolism |
1.31 |
5.00e-1 |
66/73 (90.41%) |
IMPA2;PIK3C2B;PLCG2;...
|
| Asthma |
1.31 |
4.81e-1 |
25/31 (80.65%) |
HLA-DQA1;HLA-DPB1;HLA-DOB;...
|
| Ether lipid metabolism |
1.30 |
4.78e-1 |
32/49 (65.31%) |
LPCAT1;PLAAT3;GDPD3;...
|
| Transcriptional misregulation in cancer |
1.28 |
5.13e-1 |
158/192 (82.29%) |
PROM1;NUPR1;IGF1;...
|
| MicroRNAs in cancer |
1.27 |
5.04e-1 |
146/310 (47.1%) |
DDIT4;VEGFA;PLCG2;...
|
| Prostate cancer |
1.27 |
5.08e-1 |
93/97 (95.88%) |
FGFR1;IGF1;TCF7L1;...
|
| Folate biosynthesis |
1.26 |
5.08e-1 |
23/26 (88.46%) |
AKR1C3;AKR1B10;ALPL;...
|
| Melanoma |
1.26 |
4.94e-1 |
68/72 (94.44%) |
FGFR1;IGF1;PDGFD;...
|
| Arginine biosynthesis |
1.26 |
4.78e-1 |
17/22 (77.27%) |
ARG2;GLS2;GLUL;...
|
| Hematopoietic cell lineage |
1.26 |
4.79e-1 |
90/99 (90.91%) |
HLA-DQA1;HLA-DPB1;MS4A1;...
|
| Phosphatidylinositol signaling system |
1.25 |
4.97e-1 |
82/97 (84.54%) |
IMPA2;PIK3C2B;PLCG2;...
|
| Wnt signaling pathway |
-1.26 |
4.52e-1 |
124/166 (74.7%) |
FZD6;FZD3;PRICKLE3;...
|
| Spliceosome |
-1.26 |
4.55e-1 |
101/150 (67.33%) |
SNRPF;RBM8A;SF3B2;...
|
| Natural killer cell mediated cytotoxicity |
-1.27 |
4.56e-1 |
99/131 (75.57%) |
MAP2K1;PPP3R1;TNF;...
|
| NOD-like receptor signaling pathway |
-1.27 |
4.60e-1 |
145/181 (80.11%) |
CXCL1;P2RX7;NLRP1;...
|
| Mineral absorption |
-1.34 |
4.48e-1 |
48/60 (80%) |
ATP1B3;SLC26A6;FTL;...
|
| Fatty acid biosynthesis |
-1.35 |
4.32e-1 |
16/18 (88.89%) |
HSD17B8;CBR4;ACACA;...
|
| Hypertrophic cardiomyopathy |
-1.35 |
4.29e-1 |
81/90 (90%) |
TTN;TNF;EMD;...
|
| Gastric acid secretion |
-1.36 |
4.14e-1 |
63/76 (82.89%) |
CCKBR;CALML4;KCNJ1;...
|
| Legionellosis |
-1.37 |
4.23e-1 |
51/57 (89.47%) |
CYCS;ITGB2;CXCL1;...
|
| Primary bile acid biosynthesis |
-1.39 |
3.75e-1 |
15/17 (88.24%) |
CYP7A1;CH25H;CYP27A1;...
|
| Cardiac muscle contraction |
-1.39 |
3.79e-1 |
64/87 (73.56%) |
HRC;ATP2A2;ATP2A1;...
|
| Pancreatic secretion |
-1.40 |
3.92e-1 |
87/102 (85.29%) |
ADCY6;PNLIPRP2;ADCY7;...
|
| Melanogenesis |
-1.40 |
4.04e-1 |
74/101 (73.27%) |
CREBBP;CALML4;DCT;...
|
| Alzheimer disease |
-1.40 |
4.20e-1 |
279/369 (75.61%) |
MTOR;COX6B1;PIK3C3;...
|
| Glycolysis / Gluconeogenesis |
-1.42 |
3.74e-1 |
56/67 (83.58%) |
FBP2;ADPGK;MINPP1;...
|
| Taurine and hypotaurine metabolism |
-1.42 |
3.93e-1 |
8/11 (72.73%) |
GGT1;GAD1
|
| Fat digestion and absorption |
-1.44 |
3.64e-1 |
35/43 (81.4%) |
PNLIPRP2;CD36;AGPAT1;...
|
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
-1.46 |
3.40e-1 |
79/89 (88.76%) |
IKBKB;MAP2K1;PPP3R1;...
|
| Neutrophil extracellular trap formation |
-1.49 |
2.97e-1 |
101/189 (53.44%) |
MTOR;HMGB1;ITGAL;...
|
| GnRH secretion |
-1.49 |
3.10e-1 |
60/64 (93.75%) |
PLCB1;MAP2K1;CACNA1H;...
|
| Bile secretion |
-1.51 |
2.70e-1 |
68/90 (75.56%) |
ADCY6;ADCY7;ATP1B3;...
|
| Proteasome |
-1.56 |
2.08e-1 |
44/46 (95.65%) |
POMP;IFNG;PSMC4;...
|
| PPAR signaling pathway |
-1.57 |
2.04e-1 |
66/74 (89.19%) |
ME1;GK;CYP7A1;...
|
| Protein digestion and absorption |
-1.68 |
9.99e-2 |
78/103 (75.73%) |
COL4A1;SLC7A8;SLC3A2;...
|
| Carbohydrate digestion and absorption |
-1.70 |
9.09e-2 |
37/47 (78.72%) |
PIK3CA;HK3;SLC5A1;...
|
| Renin-angiotensin system |
-1.73 |
8.44e-2 |
20/23 (86.96%) |
KLK2;PRCP;MME;...
|
| Cholesterol metabolism |
-1.76 |
8.23e-2 |
44/50 (88%) |
LRP2;CYP7A1;TSPO;...
|
| Steroid biosynthesis |
-1.81 |
5.49e-2 |
19/20 (95%) |
LBR;LIPA;SC5D;...
|
| Biosynthesis of unsaturated fatty acids |
-1.83 |
7.20e-2 |
21/27 (77.78%) |
HSD17B12;ACOX1;HACD1;...
|
| Vitamin digestion and absorption |
-1.84 |
1.34e-1 |
17/24 (70.83%) |
SLC19A1;SCARB1;BTD;...
|
